MedTrace Logo

Same Day Discharge After Coronary Stenting Trial

NCT01054365 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2017-04-04

No results posted yet for this study

Summary

In comparison to delayed hospital discharge, a strategy of early hospital discharge of patients who undergo single and multivessel stenting for type A, B, and C lesion(s) using thienopyridine and a hemostatic femoral closure device, is associated with similar clinical outcomes, but greater patient satisfaction and similar cost.

Conditions

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Leonardo Clavijo

    lead OTHER

Principal Investigators

  • Leonardo Clavijo, MD, PhD · University of Southern California

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01054365 on ClinicalTrials.gov